Replimune's RP1 Carcinoma Trial Fails to Meet Primary Endpoints
By Dean Seal A clinical trial of Replimune Group's RP1 as a treatment for cutaneous squamous cell carcinoma failed to meet its primary endpoints. The...
Source: marketwatch.com
Page 7 - Replimune Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Replimune Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Replimune Group Today - Breaking & Trending Today
Replimune's skin cancer drug fails in late-stage study
Replimune Group said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by...
Source: marketscreener.com
Replimune's skin cancer therapy fails in mid-stage study, shares plunge | WSAU News/Talk 550 AM · 99.9 FM
(Reuters) - Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove ...
Source: wsau.com
Research Analysts' Updated EPS Estimates for November 13th (AADI, ANNX, ARMK, CELC, CRK, ENZ, FUN, MDB, MERC, NSIT)
Research Analysts’ updated eps estimates for Monday, November 13th: Aadi Bioscience (NASDAQ:AADI) had its price target reduced by HC Wainwright from $45.00 to $36.00. HC Wainwright currently has a buy rating on the stock. Annexon (NASDAQ:ANNX) had its price target trimmed by Needham & Company LLC from $24.00 to $16.00. They currently have a buy […]
Source: modernreaders.com
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from Brokerages
Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in […]
Source: dailypolitical.com